<DOC>
	<DOCNO>NCT00001473</DOCNO>
	<brief_summary>This study evaluate safety effectiveness stag approach therapy Wegener 's granulomatosis systemic vasculitides use prednisone plus cyclophosphamide follow methotrexate . Vasculitides involve inflammation blood vessel ( vasculitis ) may affect brain , nerve , eye , sinus , lung , kidney , intestinal tract , skin , joint , heart site . Standard treatment prednisone cyclophosphamide effective , significant toxicity ( adverse side effect ) . Methotrexate also effective treatment less toxic , associate high rate disease recurrence use patient severe lung kidney disease . Staged therapy use cyclophosphamide first methotrexate may provide good result overall safety effectiveness . Patients 10 80 year age active Wegener 's granulomatosis , polyarteritis nodosa related systemic vasculitis may eligible study . Candidates screen medical history physical examination , blood urine test , chest X-ray , electrocardiogram ( EKG ) pulmonary function test . Other procedure , biopsy , do medically indicate . Participants treat initially 1 milligram/kilogram body weight prednisone day 2 4 mg/kg cyclophosphamide day . If disease improve significantly , prednisone gradually reduce stop , remission achieve , cyclophosphamide stop . Methotrexate start 0.3 mg/kg body weight week increase 0.5 mg/kg 2 4 week . Methotrexate therapy continue least 2 year . If end 2 year disease remain remission , methotrexate gradually reduce stop . If , hand , active disease recurs methotrexate treatment , therapy change . The new choice treatment depend severity recurrence , pre-existing medical condition , previous adverse reaction prednisone , cyclophosphamide methotrexate . Patients see periodically physical examination blood test evaluate disease activity , response therapy drug side effect . X-rays do medically indicate . Evaluations schedule month patient methotrexate 3 month every 3 month next 18 month . Patients whose disease remain remission time medication see every 6 month another 4 visit .</brief_summary>
	<brief_title>Cyclophosphamide Prednisone Followed Methotrexate To Treat Vasculitides</brief_title>
	<detailed_description>The purpose study assess efficacy safety stag treatment regimen Wegener 's granulomatosis relate vasculitides patient receive glucocorticoid plus cyclophosphamide disease onset ; cyclophosphamide switch methotrexate upon disease remission . At current time , cyclophosphamide plus glucocorticoids standard care treatment disorder . Although regimen bring marked improvement survival rate , associate significant toxicity . Methotrexate plus glucocorticoid recently investigate patient non life-threatening disease regimen appear less toxicity standard therapy may associate high rate disease relapse . By induce patient cyclophosphamide glucocorticoid switch methotrexate remission , hope combine efficacy cyclophosphamide favorable toxicity profile methotrexate . If successful , regimen could provide safe , yet effective therapeutic option would applicable patient regardless disease severity . In study , patient initially treat cyclophosphamide glucocorticoid switch cyclophosphamide methotrexate upon quiescence disease activity . If end two full year methotrexate therapy continue evidence disease remission , drug taper ultimately discontinue . Patients prospectively monitor evidence disease activity drug toxicity . Specific parameter obtain include time disease remission , rate time disease relapse , incidence drug relate adverse effect . This study open patient systemically active Wegener 's granulomatosis relate vasculitis regardless degree disease severity .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>INCLUSION CRITERIA : Documentation WG base clinical characteristic histopathological evidence vasculitis . Patients positive C PANCA glomerulonephritis evidence presence red blood cell cast proteinuria renal biopsy show necrotizing glomerulonephritis absence positive immunofluorescence immunoglobulin complement also eligible . Age 1080 year . Evidence active disease define Vasculitis Disease Activity Index great equal 3 begin CTX glucocorticoid outside institution , history Vasculitis Disease Activity Index great equal 3 time therapy initiation . EXCLUSION CRITERIA : Evidence active systemic infection , judgement investigator , great danger patient underlie vasculitis . In instance infection rule gram stain culture secretion collection fluid involved organ , may necessary obtain biopsy affected tissue microbiological histopathological study . Patients pregnant nursing infant eligible . Fertile woman must negative pregnancy test within one week prior study entry must use effective mean birth control . Processes associate increase risk MTX toxicity : acute chronic liver disease , past history alcohol abuse ( great 14 oz . 100 proof liquor equivalent per week ) , ongoing alcohol use volume discontinue upon entry study . Serological evidence infection human immunodeficiency virus , hepatitis C , positive hepatitis B surface antigen . A serological determination perform within two week begin study participation . Inability comply study guideline .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>Remission</keyword>
	<keyword>Relapse</keyword>
	<keyword>Toxicity</keyword>
	<keyword>ANCA</keyword>
	<keyword>Wegener 's Granulomatosis</keyword>
</DOC>